Маалокс®

General characteristics. Structure:

Active a veshchestvo:magniya hydroxide - 400 mg;
Algeldrat * (in the form of aluminum of the oxide hydrated) - 400 mg (200 mg of aluminum of oxide are equivalent).
* - aluminum hydroxide
Excipients: starch with sucrose (sugar confectionery), sorbitol, Mannitolum, magnesium stearate, fragrance of a peppermint, sodium saccharinate, sucrose.
Description: tablets of white color, round, flat, with slanted edges and an engraving of "Mx".

Pharmacological properties:

Pharmacodynamics. Drug neutralizes free hydrochloric acid, without causing secondary hypersecretion of hydrochloric acid. Due to the increase рН at its reception peptic activity of a gastric juice decreases. Possesses also adsorbing and enveloping action thanks to which impact of disturbing factors on a mucous membrane decreases.

Pharmacokinetics. Magnesium hydroxides and aluminum are considered as the antacids of local action which are almost not absorbed at reception in the recommended doses and, respectively, not rendering system effects.

Indications to use:

- A peptic ulcer of a stomach and duodenum in an aggravation phase.
- Acute gastroduodenit, chronic gastroduodenit with the normal or increased secretory function in an aggravation phase.
- Hernia of an esophageal opening of a diaphragm, reflux esophagitis.
- The dispeptic phenomena, such as discomfort or pains in epigastriums, heartburn, an acid eructation after errors in a diet, the excess use of ethanol, coffee, nicotine and t. п,
- The dispeptic phenomena, such as discomfort or pains in epigastriums, the heartburn, an acid eructation (and their prevention) resulting from use of some medicines (non-steroidal anti-inflammatory drugs, glucocorticosteroids, etc.).

Route of administration and doses:

Tablets should be rassasyvat or to chew carefully.
Adults and teenagers are more senior than 15 years: on 1-2 tablets 3-4 times a day in 1-2 hours after food and for the night. At a reflux esophagitis drug is accepted through short time after food. The maximum number of administrations of drug - 6 times a day. Not to take more than 12 pill a day. The course of treatment should not exceed 2-3 months. At incidental use (for example, at discomfort after errors in a diet) - accept on 1k2 to a tablet once.

Features of use:

It is necessary to observe a 2-hour interval between use of the tablets Maaloks® and other drugs and a 4-hour interval between reception of the tablets Maaloks® and ftorkhinolon (watch "Interaction with other medicines"). It is necessary to avoid long purpose of the drug Maaloks® at renal failures.
In spite of the fact that drug is released without recipe, before use of drug during pregnancy and a lactation (breastfeeding), and also at teenagers it is recommended to consult with the doctor.
Aluminum hydroxide at the low content of phosphates in food can lead to development of insufficiency of phosphorus in an organism. Therefore at aluminum hydroxide use, especially long, it is necessary to provide sufficient intake of phosphates with food.
At patients with a diabetes mellitus it is necessary to take existence in sucrose drug into account.
Drug pronitsay for X-ray.

Side effects:

At observance of the recommended dosing mode side effects are insignificant.
There can sometimes be diarrhea, a lock, nausea, vomiting, change of flavoring feelings.
At long reception of high doses can arise a hypophosphatemia (especially at the low content of phosphates in food), a hypercalcuria, a nephrocalcinosis, a hypocalcemia, osteoporosis, osteomalacy.
At patients with the accompanying renal failure are possible: increase in plasma concentration of magnesium and/or aluminum, thirst development, lowering of arterial pressure, hyporeflexia.
At prolonged use of high doses at patients with a renal failure development of encephalopathy, dementia, microcytic anemia is in rare instances possible.

Interaction with other medicines:

- Skhinidin
At simultaneous use with quinidine increase in serumal concentration of quinidine and development of overdose of quinidine is possible.
- With blockers Н^гистаминовых of receptors, propranolol, atenololy, metoprololy, chloroquine, prostacyclins, diflunisaly, digoxin, bisfosfonata, Ethambutolum, an isoniazid, ftorkhinolona, sodium fluoride, glucocorticosteroids (it is described for Prednisolonum and dexamethasone), indometacin, sodium polystyrene sulphonate, ketokonazoly, linkozamida, fenotiazinovy neuroleptics, Penicillaminum, iron salts, tetracyclines, acetylsalicylic acid (and other salicylates), phosphorus food to additives, feksofenadiny, lansoprazoly, left thyroxine
At a concomitant use with the tablets Maaloks® absorption of the listed above drugs in digestive tract decreases. In case of a 2-hour interval between reception of these drugs and the tablets Maaloks® and a 4-hour interval between reception of ftorkhinolon and the tablets Maaloks® in most cases this undesirable interaction can be avoided.
- With salicylates
At a concomitant use of salicylates and the drug Maaloks® excretion of salicylates with urine as a result of alkalization of urine under the influence of the drug Maaloks® increases.
- With citrates
At an aluminum hydroxide combination to citrates increase in plasma concentration of aluminum, in particular, at patients with a renal failure is possible.

Contraindications:

- Heavy renal failure.
- Hypersensitivity to drug components.
- Hypophosphatemia.
- Intolerance of fructose (because of existence in composition of drug of sorbitol).
- A glucose galactose sprue, insufficiency of invertase-isomaltase (because of existence in composition of drug of sucrose).
- Children's and teenage age up to 15 years. With care
- At a renal failure at long reception perhaps increases in plasma concentration of magnesium and aluminum. At these patients at prolonged use of drug in high doses development of encephalopathy, dementia, microcytic anemia is possible.
- At the patients with a porphyria who are on a hemodialysis.
- At pregnancy (see. "Pregnancy and lactation").
- At Alzheimer's disease.
- At the low content of phosphates in food (risk of development of phosphatic insufficiency).
- At a diabetes mellitus (in connection with contents as a part of sucrose tablets) Pregnancy and a lactation
At animals accurate instructions on existence of teratogenic effect at aluminum hydroxide and magnesium hydroxide are not received. Currently no specific teratogenic effects when using the drug Maaloks® are revealed during pregnancy, however, in connection with insufficiency of clinical experience, its use during pregnancy is possible, only if the potential advantage of its use for mother justifies potential risk for a fruit.
It is necessary to avoid purpose of drug during pregnancy in high doses and for a long time.
During administration of drug of Maaloks® of the termination of feeding the breast does not require.

Storage conditions:

At a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity of 5 years. Not to apply after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Chewable tablets.
On 10 tablets in the blister from PVC / aluminum foil. On 2 or 4 blisters together with the application instruction place in a cardboard pack.